- Home
- CPZ vs AGEN Comparison
CPZ vs AGEN Comparison
Compare CPZ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- AGEN
- Stock Information
- Founded
- CPZ 2019
- AGEN 1994
- Country
- CPZ United States
- AGEN United States
- Employees
- CPZ N/A
- AGEN N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPZ Finance
- AGEN Health Care
- Exchange
- CPZ Nasdaq
- AGEN Nasdaq
- Market Cap
- CPZ 306.8M
- AGEN 97.7M
- IPO Year
- CPZ N/A
- AGEN 2000
- Fundamental
- Price
- CPZ $15.63
- AGEN $4.50
- Analyst Decision
- CPZ
- AGEN Buy
- Analyst Count
- CPZ 0
- AGEN 3
- Target Price
- CPZ N/A
- AGEN $10.00
- AVG Volume (30 Days)
- CPZ 63.0K
- AGEN 346.0K
- Earning Date
- CPZ 01-01-0001
- AGEN 11-05-2024
- Dividend Yield
- CPZ 11.07%
- AGEN N/A
- EPS Growth
- CPZ N/A
- AGEN N/A
- EPS
- CPZ N/A
- AGEN N/A
- Revenue
- CPZ N/A
- AGEN $159,630,000.00
- Revenue This Year
- CPZ N/A
- AGEN N/A
- Revenue Next Year
- CPZ N/A
- AGEN $0.04
- P/E Ratio
- CPZ N/A
- AGEN N/A
- Revenue Growth
- CPZ N/A
- AGEN 60.67
- 52 Week Low
- CPZ $13.17
- AGEN $4.18
- 52 Week High
- CPZ $16.11
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- CPZ 51.16
- AGEN 40.31
- Support Level
- CPZ $15.44
- AGEN $4.50
- Resistance Level
- CPZ $15.70
- AGEN $4.78
- Average True Range (ATR)
- CPZ 0.18
- AGEN 0.29
- MACD
- CPZ -0.02
- AGEN 0.02
- Stochastic Oscillator
- CPZ 36.19
- AGEN 30.77
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).